American Oriental Bioengineering, Inc. AOB is believed to have an important competitive advantage among Chinese drug manufacturers to wade through pricing uncertainties in healthcare reform, according to Oppenheimer.
Stable drug CPIs help envision a positive outlook for OTC pharmaceuticals, and traditional Chinese medicines continue to lead top pharmacy product sales. Pricing has also remained favorable, as seen in July where traditional Chinese medicines were +11.8% y/y vs. western drugs reports of +0.8%, Oppenheimer reports.
Top picks also include Tongjitang Chinese Medicines Company TCM and BMP Sunstone Corporation BJGP.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorLong IdeasNewsPre-Market OutlookIntraday UpdateAnalyst RatingsAOBBJGPConsumer StaplesHealth CareHealth Care DistributorsOppenheimerPersonal ProductsPharmaceuticalsTCM
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in